Illustration: Aïda Amer/Axios
Western pharmaceutical companies are increasingly turning to Chinese biotechs for new drugs as China gains ground in novel drug development.
Why it matters: The shift is intensifying competition for licensing deals — a crucial source of funding for early-stage U.S. biotechs.
